Blood Screening

Blood Screening

Global Blood Screening Market to Reach US$3.8 Billion by 2030

The global market for Blood Screening estimated at US$2.6 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Nucleic Acid Test (NAT), one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Enzyme-Linked Immunosorbent Assay (ELISA) segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$697.7 Million While China is Forecast to Grow at 9.1% CAGR

The Blood Screening market in the U.S. is estimated at US$697.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$831.4 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Blood Screening Market - Key Trends and Drivers Summarized

Why Is Blood Screening Essential in Ensuring Safe Healthcare Practices?

Blood screening is a critical process in healthcare, designed to detect infectious agents, genetic disorders, and other health conditions in blood samples before they are used for transfusions, organ transplants, or diagnostic purposes. This screening process is vital to ensuring that blood and blood products are safe for use, thereby preventing the transmission of diseases such as HIV, hepatitis, and syphilis. Blood screening also plays a crucial role in the early detection of conditions like cancer and inherited genetic disorders, allowing for timely intervention and treatment. The accuracy and reliability of blood screening tests are paramount, as they directly impact patient safety and public health. As the demand for safe blood products continues to rise globally, blood screening has become an indispensable component of modern healthcare, protecting patients and ensuring the efficacy of medical treatments.

How Has the Evolution of Technology Transformed Blood Screening Processes?

The field of blood screening has been revolutionized by advancements in technology, leading to faster, more accurate, and comprehensive testing methods. Traditionally, blood screening relied on manual techniques and basic serological tests, which, while effective, were limited in scope and could take days to yield results. The introduction of automated testing systems and molecular diagnostics has drastically improved the speed and accuracy of blood screening. Techniques such as nucleic acid testing (NAT) allow for the detection of viral and bacterial pathogens at a much earlier stage, reducing the risk of transmitting infections through blood transfusions. Additionally, the development of high-throughput screening systems has enabled the processing of large volumes of blood samples more efficiently, which is crucial in meeting the demands of modern healthcare facilities. As a result, the evolution of blood screening technology has not only enhanced the safety of blood products but has also expanded the range of detectable conditions, making it a cornerstone of preventive healthcare.

What Are the Emerging Trends and Innovations in Blood Screening Technology?

Blood screening is currently undergoing significant innovation, driven by the need for more comprehensive, faster, and cost-effective diagnostic solutions. One of the most notable trends is the growing use of next-generation sequencing (NGS) in blood screening, which allows for the detailed analysis of genetic material and the identification of a wide range of pathogens and genetic disorders from a single blood sample. Another emerging trend is the integration of artificial intelligence (AI) and machine learning into blood screening processes, which enhances the accuracy of diagnostics by identifying patterns and anomalies that might be missed by conventional methods. Furthermore, the development of point-of-care (POC) testing devices is transforming blood screening by enabling rapid testing in various settings, including remote and resource-limited areas, thus improving access to critical diagnostics. These innovations are pushing the boundaries of what is possible in blood screening, offering the potential for earlier detection, more personalized treatment options, and improved patient outcomes.

What Are the Factors Fueling Expansion of the Blood Screening Market?

The growth in the blood screening market is driven by several critical factors that underscore the increasing importance of safe and accurate diagnostics in healthcare. One of the primary drivers is the rising demand for blood and blood products, particularly in emerging markets where healthcare infrastructure is expanding. As more surgeries, transfusions, and transplants are performed, the need for rigorous blood screening to prevent the transmission of infectious diseases is becoming more urgent. Technological advancements, such as the adoption of nucleic acid testing (NAT) and next-generation sequencing (NGS), are also fueling market growth by offering more precise and efficient screening options. Additionally, the increasing prevalence of chronic diseases and the growing focus on early detection and preventive care are boosting the demand for comprehensive blood screening tests. The global push for improved public health standards, supported by government initiatives and regulations, is further driving the expansion of the blood screening market. These factors, combined with ongoing innovations in diagnostic technology, highlight the critical role of blood screening in modern healthcare, ensuring the safety and well-being of patients worldwide.

Select Competitors (Total 12 Featured) -
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols International SA
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Blood Screening – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Safe Blood Donations Throws the Spotlight on Advanced Blood Screening Technologies
Increasing Incidence of Bloodborne Diseases Drives Demand for Comprehensive Blood Screening Tests
Advancements in Molecular Diagnostics Propel Growth in Rapid and Accurate Blood Screening Solutions
Shift Toward Early Disease Detection Expands Addressable Market Opportunity for Blood Screening Innovations
Innovations in High-Throughput Screening Accelerate Demand for Efficient Blood Testing Systems
Expansion of Point-of-Care Diagnostics Spurs Growth in Portable and Rapid Blood Screening Devices
Integration of AI in Diagnostics Drives Adoption of Automated Blood Screening Systems
Innovations in Sample Collection and Processing Are Enhancing Blood Screening Accuracy
Growing Importance of Infection Control Expands Market Penetration for Comprehensive Blood Screening Solutions
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Blood Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Nucleic Acid Test (NAT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Western Blot Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Blood Banks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 35: USA Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: USA Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: USA 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
CANADA
TABLE 44: Canada Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Canada 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Canada 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
JAPAN
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 53: Japan Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Japan 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Japan 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
CHINA
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 62: China Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: China Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: China 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: China Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: China 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: China Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: China 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
EUROPE
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 71: Europe Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Europe 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Europe 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
FRANCE
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 83: France Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: France Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: France 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: France Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: France 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: France Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: France 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
GERMANY
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 92: Germany Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Germany 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Germany 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Germany 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
ITALY
TABLE 101: Italy Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Italy 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Italy 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Italy 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
UNITED KINGDOM
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 110: UK Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: UK Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: UK 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: UK Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: UK 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: UK Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: UK 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
SPAIN
TABLE 119: Spain Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Spain Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Spain 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 122: Spain Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Spain 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Spain 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
RUSSIA
TABLE 128: Russia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Russia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Russia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 131: Russia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Russia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Russia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Rest of Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Rest of Europe 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of Europe 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of Europe 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 147: Asia-Pacific Historic Review for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Asia-Pacific 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Asia-Pacific 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Asia-Pacific 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Asia-Pacific 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
AUSTRALIA
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 158: Australia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Australia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Australia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 161: Australia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Australia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Australia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
INDIA
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 167: India Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: India Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: India 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 170: India Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: India Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: India 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: India Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: India 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 176: South Korea Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: South Korea Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: South Korea 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 179: South Korea Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: South Korea 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: South Korea 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Rest of Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
LATIN AMERICA
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 194: Latin America Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 195: Latin America Historic Review for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Latin America 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 197: Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Latin America 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Latin America 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Latin America 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 206: Argentina Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Argentina Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Argentina 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 209: Argentina Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Argentina 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Argentina 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
BRAZIL
TABLE 215: Brazil Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 216: Brazil Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 217: Brazil 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 218: Brazil Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 220: Brazil 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 223: Brazil 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
MEXICO
TABLE 224: Mexico Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 225: Mexico Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 226: Mexico 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 227: Mexico Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 229: Mexico 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 232: Mexico 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 234: Rest of Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 235: Rest of Latin America 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 238: Rest of Latin America 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 241: Rest of Latin America 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
MIDDLE EAST
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 242: Middle East Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 243: Middle East Historic Review for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 244: Middle East 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 245: Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 247: Middle East 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 250: Middle East 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 253: Middle East 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
IRAN
TABLE 254: Iran Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 255: Iran Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 256: Iran 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 257: Iran Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 259: Iran 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 262: Iran 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
ISRAEL
TABLE 263: Israel Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 264: Israel Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 265: Israel 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 266: Israel Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 268: Israel 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 271: Israel 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 273: Saudi Arabia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 274: Saudi Arabia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 277: Saudi Arabia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 280: Saudi Arabia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 281: UAE Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 282: UAE Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 283: UAE 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 284: UAE Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 286: UAE 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 289: UAE 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 291: Rest of Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 292: Rest of Middle East 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 295: Rest of Middle East 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 298: Rest of Middle East 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
AFRICA
Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 299: Africa Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 300: Africa Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 301: Africa 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
TABLE 302: Africa Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 304: Africa 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 307: Africa 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings